Athira Pharma (NASDAQ:ATHA) is a forward-thinking biotechnology company focused on developing therapies for neurodegenerative diseases. The company, listed on the NASDAQ, channels its efforts into innovative treatments aimed at slowing and potentially reversing the effects of conditions like Alzheimer's and Parkinson's disease. Athira is actively working on its leading project, fosgonimeton, a treatment that targets synaptic health and neuron connectivity, critical factors in cognitive function. By prioritizing research and development, Athira aims to address unmet medical needs and improve patients’ lives through breakthrough therapies. Their ultimate objective is to create groundbreaking solutions that tackle the underlying causes of neurodegeneration.